Hit a Plateau on a GLP-1? What to Review and What the Trials Show

You were losing a pound or two a week, your clothes were looser, and then the scale simply stopped. If you are taking semaglutide or tirzepatide, that moment can feel alarming: did the medicine stop working, did you do something wrong, or is it time to ask for a higher dose?

The research offers a calmer picture. Weight loss on GLP-1 medications follows a predictable curve, and a plateau is part of that curve for almost everyone. This guide explains when plateaus usually appear in clinical trials, how to tell a true plateau from a slow stretch, what commonly drives a stall, and which questions are worth reviewing with your prescriber. It is general education, not personal medical advice, and it never replaces the person who manages your treatment.

The short answer

A plateau on a GLP-1 is normal and expected. Weight falls fastest in the first months, slows, and then levels off at a new balance point where the calories you eat roughly match the calories your smaller body burns. In the STEP 1 trial of semaglutide 2.4 mg, average weight loss reached its lowest point around week 60. In an analysis of the SURMOUNT-1 tirzepatide trial, most people who lost meaningful weight had reached a plateau by week 72, with a median time of roughly 24 to 36 weeks depending on starting BMI.

Before you decide you are stuck, check your weight trend over at least three to four weeks. Then review a short list with your care team: missed or late doses, whether you have reached a maintenance dose, eating and drinking habits that may have drifted, protein and strength training, daily movement, other medicines, and whether your current weight might already be a healthy place to hold. Changes to dose or medication are your prescriber’s call. Stopping treatment because of a plateau usually leads to regain.

First: is it really a plateau?

Daily weight can swing by a few pounds because of water, salt, carbohydrate intake, hormones, bowel habits and the time you weigh yourself. Mayo Clinic explains that early weight loss is partly water released from glycogen, a stored form of carbohydrate in muscle and liver, and that this effect is temporary. Constipation, which is common on GLP-1 medications, can also add weight on the scale without any fat gain. Our guide to constipation and diarrhea on GLP-1s covers that side of things.

Because of this noise, a single weigh-in tells you very little. A more useful approach:

• Look at weekly averages. Weigh at the same time of day, under the same conditions, and compare the average of each week rather than individual days.
• Give it time. A flat trend for one or two weeks is often just noise. Three to four weeks of no movement is more meaningful, and researchers use even longer windows.
• Check other measures. Waist size, how clothes fit, energy, blood pressure and blood sugar can keep improving while the scale is quiet.

For comparison, the tirzepatide plateau analysis described below used a strict research definition: weight changing by less than 5% over a 12-week window and every 12-week window after it. That is a definition for comparing trial participants, not a rule for you, but it shows that researchers think about plateaus over months, not days.

When GLP-1 weight loss usually levels off

Clinical trials give the clearest picture of the typical curve, because they weigh large numbers of people on a fixed schedule.

Study	What was tested	What it showed about timing
STEP 1 (NEJM, 2021)	Semaglutide 2.4 mg vs placebo for 68 weeks, 1,961 adults without diabetes	Average weight change −14.9% vs −2.4%; the trial report notes the lowest point came around week 60
SURMOUNT-1 (NEJM, 2022)	Tirzepatide 5, 10 or 15 mg vs placebo for 72 weeks	Average weight change −15.0%, −19.5% and −20.9% vs −3.1%
Time-to-plateau analysis of SURMOUNT-1 and SURMOUNT-4 (Clinical Obesity, 2025)	1,438 SURMOUNT-1 participants who took tirzepatide as directed and lost at least 5%	Median time to plateau 24.3, 26.0, 36.1 and 36.1 weeks for overweight, class I, II and III obesity; about 88% to 90% had plateaued by week 72
STEP 4 (JAMA, 2021)	20 weeks of semaglutide for everyone, then continue or switch to placebo for 48 weeks	Continuing: a further −7.9%. Switching to placebo: +6.9%

A few details from the tirzepatide analysis are especially useful for setting expectations:

• Most of the loss happens early. Across BMI groups, average weight loss in the first 24 weeks was about 13% to 15%. Between weeks 24 and 72, people starting with higher BMIs lost more additional weight (about 7% to 10%) than people starting in the overweight range (about 4.6%).
• Some people plateau later. Higher doses (10 or 15 mg vs 5 mg), younger age and female sex were linked with a longer time to plateau. On average, the plateau came 6.7 weeks later on 15 mg than on 5 mg and 4.2 weeks later in women than in men.
• These are trial averages. Participants received regular visits and lifestyle counseling, took their doses as directed, and had to lose at least 5% to be included in the analysis. Your own curve may look different.

For a month-by-month view of how this plays out, see our GLP-1 weight-loss timeline, and for the full trial details, our summaries of semaglutide clinical trial results and tirzepatide clinical trial results.

Why weight loss stalls on a GLP-1

GLP-1 medications work mainly by reducing appetite and how much you eat. The STEP 1 investigators described the weight loss as stemming from reduced energy intake due to decreased appetite. They do not cancel the basic rules of energy balance, so the same forces that end any diet’s weight loss eventually catch up:

1. A smaller body needs less energy. As Mayo Clinic puts it, when the calories you burn equal the calories you eat, you reach a plateau. A meal size that created a deficit at your starting weight may be roughly maintenance at your new weight. Our explainer on whether weight loss slows your metabolism walks through how large that drop usually is.
2. Appetite pushes back. After weight loss, the body’s hunger signals rise. GLP-1 medicines blunt this, which is why trial weight loss continues for many months, but they do not remove it entirely. Our guide to why weight loss plateaus happen explains this feedback in more depth.
3. Habits drift. Early on, nausea and fullness make small portions easy. As side effects fade, portions, snacks, drinks and weekend eating can creep back without you noticing. Mayo Clinic notes that off-and-on loosening of habits contributes to plateaus.
4. Movement drops. When you feel tired or are eating less, everyday activity outside formal exercise often declines, and that is the part of calorie burn that changes most.

Early stalls are not the same as a true plateau

Many people notice a pause in the first few months, while their dose is still being raised. Prescribing information for both medicines builds in gradual steps to reduce stomach side effects: semaglutide (Wegovy) starts at 0.25 mg weekly and rises every four weeks to a maintenance dose of 1.7 mg or 2.4 mg from week 17, and tirzepatide (Zepbound) starts at 2.5 mg, which is not a maintenance dose, then rises in 2.5 mg steps after at least four weeks to a maintenance dose of 5, 10 or 15 mg.

That matters for two reasons. First, weight loss during the starting weeks is often slower simply because the dose is low. Second, a slow start does not necessarily predict a poor result. In a post hoc analysis of STEP 4, people who had lost at least 5% by week 20 of semaglutide went on to lose an average of 19.7% by week 68. People who had not reached 5% by week 20 still lost an average of 6.4% when they kept taking it, compared with 0.3% after switching to placebo, and being a slow early responder had limited value for predicting who would fall short. A 2023 modeling study from STEP trial data found that predictions of one-year weight loss became much more accurate as more weeks of weight data were included, especially once people were nearing the full dose around week 16.

In other words, judging a GLP-1 at week six is premature. Your prescriber will usually want to see how you respond once you have spent some time on a maintenance dose.

What to review before changing anything

Here is a checklist many clinicians work through when someone reports a stall. Use it to prepare for your appointment rather than as a do-it-yourself treatment plan.

Question	Why it matters
Am I taking every dose on schedule?	Missed or delayed doses lower drug levels. Labels give specific missed-dose rules; Wegovy’s, for example, depends on whether the next dose is more or less than 2 days away, and after 2 or more missed doses your prescriber may restart the dose steps.
Have I reached a maintenance dose, and which one?	In a real-world study of 7,881 patients, 80.8% were on low maintenance doses, and average weight loss was smaller than in trials.
Have I had any gaps in supply?	In the same study, people who stopped within 3 months lost 3.6% at one year, versus 11.9% for those who kept going.
Have portions, snacks or drinks crept up?	A few days of honest tracking, including drinks, oils and weekends, often reveals the gap. Alcohol adds calories and can loosen food choices; see our guide to alcohol and GLP-1s.
Am I eating enough protein and strength training?	Both help protect muscle during weight loss. See how much protein you need on a GLP-1 and strength training on GLP-1s.
Has my daily movement dropped?	Steps and general activity tend to fall as energy dips. Mayo Clinic suggests at least 150 minutes a week of moderate activity, and more for weight-loss maintenance; see walking for weight loss.
Did I start any new medicines?	The Endocrine Society notes that many drugs prescribed for diabetes, depression and other chronic conditions can promote weight gain.
Could a health condition be involved?	New fatigue, feeling cold, swelling or other symptoms are worth raising; your clinician may decide whether tests such as thyroid checks make sense.
Is my current weight already a healthy place to hold?	Your clinician can help decide whether further loss is needed or whether maintenance is the right next phase.

An updated estimate of your energy needs from our TDEE calculator can be a helpful reference point, and our explainer on what a calorie deficit is covers how a deficit shrinks as you lose weight.

Questions your prescriber may weigh

After reviewing the basics, your clinician may discuss several directions. This is a description of what the prescribing information and research cover, not a recommendation for you.

Dose. Both labels say to consider treatment response and tolerability when choosing a maintenance dose. For tirzepatide (Zepbound), the label lists 5, 10 or 15 mg weekly, with 15 mg as the maximum. For semaglutide, the FDA approved a higher 7.2 mg dose (Wegovy HD) on March 19, 2026. According to the manufacturer’s announcement, it is for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. In the 72-week STEP UP trial of 1,407 adults with obesity and without diabetes, average weight loss was 20.7% with 7.2 mg, 17.5% with 2.4 mg and 2.4% with placebo when people stayed on treatment. The FDA noted that altered skin sensations, such as sensitivity, pain or burning, were common and more frequent at the higher dose; the company reported them in 22% on 7.2 mg versus 6% on 2.4 mg.

Medication choice. In the SURMOUNT-5 trial, which directly compared the two drugs at their maximum tolerated doses in 751 adults with obesity and without type 2 diabetes, average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide. Whether a switch makes sense depends on your history, side effects, coverage and goals. Our semaglutide vs tirzepatide roundup and the Tirzepatide hub have more background.

Support beyond medication. Nutrition counseling, structured activity, sleep and stress support, and other obesity treatments can all be part of the conversation.

Whether to keep losing at all. In a YouTube video on GLP-1 plateaus, a triple-board-certified obesity medicine physician says the first thing he does with a plateaued patient is decide whether they actually need to lose more weight. He contrasts someone who still has sleep apnea, prediabetes or joint pain with someone who is now at a healthy weight with no metabolic problems. For the second person, the goal shifts to keeping the weight off.

If you have type 2 diabetes

Expect a different curve. In STEP 2, adults with overweight or obesity and type 2 diabetes lost an average of 9.6% of body weight on semaglutide 2.4 mg at 68 weeks, compared with 14.9% in the STEP 1 trial of people without diabetes. In the STEP UP trial of the 7.2 mg dose in people with type 2 diabetes, the manufacturer reports average weight loss of 14.1%. A plateau at a smaller percentage is common in this group and does not mean treatment is failing; blood sugar control is part of the benefit. If you use insulin or a sulfonylurea, cutting calories sharply on your own can raise the risk of low blood sugar, so make changes with your care team.

Why a plateau is not a reason to quit

A plateau often means the medicine has changed jobs: from helping you lose weight to helping you hold it. The STEP 4 trial tested this directly. Everyone took semaglutide for 20 weeks, and those who completed that period had lost an average of 10.6%. Those who continued lost another 7.9% over the next 48 weeks, while those switched to placebo regained 6.9%.

Real-world data point the same way. In a Cleveland Clinic study of 7,881 adults who started semaglutide or tirzepatide for obesity, average one-year weight loss was 8.7% overall, lower than in trials. The researchers linked this to higher discontinuation rates and lower maintenance doses. People who did not stop and were on higher maintenance doses lost 13.7% with semaglutide and 18.0% with tirzepatide.

For more on what happens long-term, see our guide on how to maintain weight loss and the GLP-1 Guide hub, which covers long-term use.

What not to do

• Don’t change your dose on your own. Do not take extra doses, inject more often or skip dose steps. Labels set minimum times on each dose to limit side effects.
• Don’t buy “research-use” or unapproved products to break a stall. On X, people chasing plateaus often talk up experimental drugs that are not approved, and some sellers market them directly. Products sold outside a pharmacy and a prescription have no quality guarantees.
• Don’t crash diet. Mayo Clinic advises against cutting below 1,200 calories a day because constant hunger raises the risk of overeating. Very low intake can also make it harder to get enough protein.
• Don’t judge by one weigh-in. Water, constipation and salt can mask weeks of fat loss.
• Don’t blame yourself. Plateaus come from predictable biology, not a lack of willpower.

What people are saying online

On X, plateau posts tend to fall into three camps. One group shares simple checklists along the lines of “check your protein, lift two to three times a week, sleep seven or more hours, ask your prescriber about the dose,” which closely matches what the evidence supports. A second group points to slower digestion and constipation as a reason the scale stalls, especially in people over 40. A third talks about experimental next-generation drugs as the way to “break through.” Those drugs are still being studied, and trial results are not the same as approval. The most useful thread running through all of it: a stalled scale does not automatically mean the plan has failed.

When to talk to your clinician

Contact your prescriber if your weight has been flat for two to three months on a stable dose, if you are regaining, if side effects are making it hard to eat enough protein or stay active, or if you notice new symptoms like ongoing fatigue, swelling or changes in mood. Seek urgent care for severe, persistent abdominal pain, which can be a sign of a serious problem. Bring your weekly weight averages, a short food and activity log, and a complete list of your medicines and supplements. That turns a frustrating visit into a productive one.

The bottom line

Plateaus on GLP-1 medications are expected. In trials, weight loss is fastest over the first six months or so and usually levels off somewhere between about six and fourteen months, later at higher doses and higher starting weights. Before assuming you are stuck, look at your trend over several weeks, then review dose timing, maintenance dose, eating drift, protein, strength training, movement, other medicines and your goal with your care team. Dose increases, medication switches and other treatments are options your prescriber can weigh. Stopping treatment because the scale stopped moving often undoes the progress, because the plateau is usually the medicine helping you hold your new weight.

Keep exploring in the Plateaus & Maintenance hub, the Semaglutide hub and the Tirzepatide hub, or start with our first 30 days guide if you are new to treatment.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical advice, diagnosis or treatment. Never start, stop or change a medication, dose, diet or exercise program without talking to a licensed clinician.